TX HB3057

Requires health benefit plans that cover chimeric antigen receptor (CAR) T-cell therapy to provide coverage when the treatment is medically necessary and administered by an FDA-certified facility that participates in the plan's network

Applies to a broad range of health plans including insurance companies, HMOs, group hospital service corporations, small employer plans, state employee plans (Chapter 1551), teacher plans (Chapter 1575), and university employee plans (Chapter 1601)

Exempts Medicaid, Medicaid managed care, and the Children's Health Insurance Program (CHIP) from the coverage requirements

Directs the Insurance Commissioner to adopt rules necessary to administer the new subchapter

Takes effect September 1, 2025, and applies to health benefit plans delivered, issued, or renewed on or after January 1, 2026